<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sclerosing agent for lower extremity venous disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sclerosing agent for lower extremity venous disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Sclerosing agent for lower extremity venous disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="11" width="9%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Class</td> <td class="subtitle1">Formulation</td> <td class="subtitle1">Composition</td> <td class="subtitle1">Test dose</td> <td class="subtitle1">Advantages</td> <td class="subtitle1">Disadvantages</td> <td class="subtitle1">Vessel size (mm)</td> <td class="subtitle1">Concentration (%)</td> <td class="subtitle1">Injection/vein (mL)</td> <td class="subtitle1">Max dose</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Polidocanol (Aethoxysclerol)</td> <td class="divider_bottom" rowspan="6">Detergent</td> <td class="divider_bottom" rowspan="6"> <p>1%</p> 3%</td> <td class="divider_bottom" rowspan="6">Hydroxypolyethoxydodecane, distilled, ethyl alcohol</td> <td class="divider_bottom" rowspan="6">0.5 mL</td> <td class="divider_bottom" rowspan="6"> <ul> <li>Painless</li> <li>Not toxic to tissue</li> <li>Rare ulceration</li> <li>No skin necrosis</li> </ul> </td> <td class="divider_bottom" rowspan="6"> <ul> <li>Allergy</li> <li>Telangiectatic matting</li> <li>Hyperpigmentation</li> <li>No necrosis with extravasation</li> </ul> </td> <td>&lt;0.5</td> <td>0.25 to 0.5</td> <td>0.25</td> <td>3% solution</td> </tr> <tr> <td>0.5 to 1</td> <td>0.5 to 0.75</td> <td>0.5</td> <td>50 kg: 5 mL</td> </tr> <tr> <td>1 to 3</td> <td>0.75 to 1</td> <td>0.5 to 0.75</td> <td>60 kg: 6 mL</td> </tr> <tr> <td>3 to 5</td> <td>1 to 2</td> <td>0.75 to 1</td> <td>70 kg: 7 mL</td> </tr> <tr> <td>&gt;5</td> <td>3 to 5</td> <td>To max</td> <td>80 kg: 8 mL</td> </tr> <tr class="divider_bottom"> <td> </td> <td> </td> <td> </td> <td>90 kg: 9 mL</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Hypertonic saline*</td> <td class="divider_bottom" rowspan="5">Osmotic</td> <td class="divider_bottom" rowspan="5"> <p>14.6%</p> 23.4%</td> <td class="divider_bottom" rowspan="5">Sodium chloride</td> <td class="divider_bottom" rowspan="5">Not required</td> <td class="divider_bottom" rowspan="5"> <ul> <li>No allergy</li> </ul> </td> <td class="divider_bottom" rowspan="5"> <ul> <li>Pain</li> <li>Muscle cramping</li> <li>Ulceration/necrosis</li> <li>Hyperpigmentation</li> </ul> </td> <td>&lt;0.5</td> <td>11.7 to 15</td> <td>0.25</td> <td class="divider_bottom" rowspan="5">None<sup>¶</sup></td> </tr> <tr> <td>0.5 to 1</td> <td>11.7 to 15</td> <td>0.5</td> </tr> <tr> <td>1 to 3</td> <td>15 to 23.4</td> <td>0.5 to 1</td> </tr> <tr> <td>3 to 5</td> <td>–</td> <td>–</td> </tr> <tr class="divider_bottom"> <td>&gt;5</td> <td>–</td> <td>–</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Sodium tetradecyl sulfate</td> <td class="divider_bottom" rowspan="4">Detergent</td> <td class="divider_bottom" rowspan="4"> <p>1%</p> 3%</td> <td class="divider_bottom" rowspan="4">Sodium 1-isobutyl-4thyloctyl sulfate, benzoyl alcohol 2%, phosphate</td> <td class="divider_bottom" rowspan="4">0.5 mL</td> <td class="divider_bottom" rowspan="4"> <ul> <li>Less telangiectatic matting</li> </ul> </td> <td class="divider_bottom" rowspan="4"> <ul> <li>Allergy</li> <li>Hyperpigmentation</li> <li>Ulceration/necrosis</li> <li>Epidermal necrosis with extravasation at higher concentrations</li> </ul> </td> <td>0.2 to 1</td> <td>0.1 to 0.3</td> <td>0.25</td> <td class="divider_bottom" rowspan="4">10 mL of 3% solution<sup>Δ</sup></td> </tr> <tr> <td>1 to 3</td> <td>0.25 to 0.5</td> <td>0.5</td> </tr> <tr> <td>3 to 5</td> <td>0.5 to 1</td> <td>0.5 to 1</td> </tr> <tr class="divider_bottom"> <td>&gt;5</td> <td>1.5 to 3</td> <td>To max</td> </tr> <tr> <td>Glycerin</td> <td>Osmotic</td> <td>72%</td> <td>Glycerol, 1, 2, 3-propanetrial, glycerine</td> <td>0.5 mL</td> <td> <ul> <li>No matting</li> <li>No ulceration</li> <li>No necrosis</li> </ul> </td> <td> <ul> <li>Highly allergenic due to chromate moiety</li> <li>Contact sensitivity</li> <li>Rare: Hematuria</li> <li>Urethral colic</li> <li>Difficult to work with (extremely viscous)</li> </ul> </td> <td>&lt;1</td> <td>25 to 72</td> <td>0.25</td> <td>10 mL of 72% solution</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Hypertonic saline/glucose combination (Sclerodex) is available outside the United States.<br/>¶ None labeled. Limit use as with any product with saline.<br/>Δ United States and Canada (elsewhere see drug insert).</div><div class="graphic_reference">Data from:

<ol>
<li>Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; 18:CD001732.</li>
<li>Goldman MP. Treatment of varicose and telangiectatic leg veins: Double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002; 28:52.</li>
<li>Parsi K, Exner T, Connor DE, et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34:731.</li>
<li>Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: Hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16:800.</li>
<li>Bukhari RH, Lohr JM, Paget DS, et al. Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy. J Vasc Surg 1999; 29:479.</li>
<li>Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: A retrospective analysis. J Dermatol Surg Oncol 1990; 16:327.</li>
<li>Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: Effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20:643.</li>
</ol></div><div id="graphicVersion">Graphic 70171 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
